Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 9/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | FAP | Q12884 | 3/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14102477 | 0.87 | ALDH1A1 (0.49) | ALDH1A1DPP4KCNH2FAPPREP | |
| SCHEMBL8294401 | 0.86 | TDP1 (0.56) | KLK5TDP1 | |
| SCHEMBL6298469 | 0.86 | TDP1 (0.56) | KLK5TDP1 | |
| SCHEMBL4770561 | 0.86 | ALDH1A1 (0.47) | KLK5ACEALDH1A1DPP4POLB | |
| SCHEMBL7852576 | 0.85 | DPP4 (0.61) | KLK5ACEDPP4DPP9 | |
| SCHEMBL14421765 | 0.84 | KLK5 (0.48) | KLK5ACEDPP4DPP9 | |
| SCHEMBL4921729 | 0.83 | CTSK (0.47) | ALDH1A1 | |
| SCHEMBL8505388 | 0.83 | CTSK (0.47) | ALDH1A1 | |
| SCHEMBL8290087 | 0.82 | DPP4 (0.49) | KLK5ACEDPP4DPP9CMA1 | |
| SCHEMBL4663334 | 0.82 | DPP4 (0.49) | KLK5ACEDPP4DPP9CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | KLK5 1019/4885ACE 20/4885ALDH1A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.